Methodological assessment of HCC literature

Area of Science:

• Hepatology
• Oncology
• Clinical Trial Methodology

Background:

• Hepatocellular carcinoma (HCC) is a significant health concern with limited approved treatments, notably only sorafenib for advanced stages.
• Few interventions for HCC have undergone rigorous evaluation compared to other lethal cancers.
• Existing clinical trials for HCC often suffer from design flaws and methodological weaknesses.

Purpose of the Study:

• To critically review the methodological challenges in hepatocellular carcinoma (HCC) clinical trials.
• To identify issues hindering the rational development of novel HCC treatments.
• To bridge the gap between clinical trial outcomes and practical clinical application in HCC management.

Main Methods:

• Literature review focusing on clinical trial design and methodology in HCC research.
• Analysis of common pitfalls in HCC study protocols and data interpretation.
• Discussion of evidence strength in current HCC treatment guidelines.

Main Results:

• A significant disparity exists between evaluated interventions for HCC and other highly lethal tumors.
• Methodological issues in HCC trials lead to low-strength evidence in treatment recommendations.
• A gap frequently observed between trial endpoints and real-world clinical needs for HCC patients.

Conclusions:

• Addressing methodological flaws in HCC clinical trials is crucial for advancing treatment options.
• Improved trial design is necessary to generate robust evidence for HCC therapies.
• Rational drug development for HCC requires overcoming existing research and guideline limitations.